(Q28304657)

2

0 references

Xiaolin Niu

3

0 references

Jin Wei

4

0 references

Ping Sun

5

0 references

Guanghua Hao

Journal of Clinical Hypertension

6

0 references

language of work or name

English

0 references

publication date

May 2011

0 references

published in

0 references

volume

24

0 references

issue

5

0 references

page(s)

613-21

0 references

cites work

Cardiovascular morbidity and mortality in high-risk populations: epidemiology and opportunities for risk reduction

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.3

Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.3

Progression of cardiovascular damage: the role of renin-angiotensin system blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.3

Protective effects of renin-angiotensin blockade beyond blood pressure control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.3

Renin inhibition: what are the therapeutic opportunities?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.3

Renin inhibition: new potential for an old therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.3

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.3

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.3

Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.3

Combination therapy with various combinations of aliskiren, valsartan, and hydrochlorothiazide in hypertensive patients not adequately responsive to hydrochlorothiazide alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.3

Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.3

Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.3

Direct Renin inhibition with aliskiren in obese patients with arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.3

Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.3

Telmisartan, ramipril, or both in patients at high risk for vascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.3

Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.3

Aliskiren combined with losartan in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.3

Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.3

Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.3

inferred from DOI database lookup

7 January 2021

based on heuristic

Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.3

inferred from DOI database lookup

7 January 2021

based on heuristic

Blood pressure control and pharmacotherapy patterns in the United States before and after the release of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) guidelines

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.3